Experimental immune cell therapy shows promise for Hard-to-Treat cancers
NCT ID NCT05729399
First seen May 03, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. Doctors took immune cells from each patient's tumor, multiplied them in a lab, and infused them back after a short course of chemotherapy. The goal was to see if this approach was safe and could shrink tumors. Only 6 people enrolled before the study ended early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.